Evaluating the clinical significance of SHMT2 and its co-expressed gene in human kidney cancer
- PDF / 2,348,668 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 198 Views
(2020) 53:46 Wang et al. Biol Res https://doi.org/10.1186/s40659-020-00314-2
Open Access
ORIGINAL PAPER
Evaluating the clinical significance of SHMT2 and its co‑expressed gene in human kidney cancer Huan Wang1,2,3, Tie Chong1*, Bo‑Yong Li2,3, Xiao‑San Chen2,3 and Wen‑Bo Zhen2,3
Abstract Background: Kidney cancer is one of the most common cancers in the world. It is necessary to clarify its underlying mechanism and find its prognostic biomarkers. Current studies showed that SHMT2 may be participated in several kinds of cancer. Methods: Our studies investigated the expression of SHMT2 in kidney cancer by Oncomine, Human Protein Atlas database and ULCAN database. Meanwhile, we found its co-expression gene by cBioPortal online tool and validated their relationship in A498 and ACHN cells by cell transfection, western blot and qRT-PCR. Besides these, we also explored their prognostic values via the Kaplan–Meier plotter database in different types of kidney cancer patients. Results: SHMT2 was found to be increased in 7 kidney cancer datasets, compared to normal renal tissues. For the cancer stages, ages and races, there existed significant difference in the expression of SHMT2 among different groups by mining of the UALCAN database. High SHMT2 expression is associated with poor overall survival in patients with kidney cancer. Among all co-expressed genes, NDUFA4L2 and SHMT2 had a high co-expression efficient. SHMT2 over‑ expression led to the increased expression of NDUFA4L2 at both mRNA and protein levels. Like SHMT2, overexpressed NDUFA4L2 also was associated with worse overall survival in patients with kidney cancer. Conclusion: Based on above results, overexpressed SHMT2 and its co-expressed gene NDUFA4L2 were all correlated with the prognosis in kidney cancer. The present study might be benefit for better understanding the clinical signifi‑ cance of SHMT2 and provided a potential therapeutic target for kidney cancer in future. Keywords: SHMT2, NDUFA4L2, Prognosis, Kidney cancer, Bioinformatic analysis Background Kidney cancer, as one of the most common cancers in the world, is becoming a severe global burden but lacks public attention [1]. Among various types of kidney cancer, clear cell renal cell carcinoma (ccRCC) was the most common subtype of kidney cancer, accounting for more than 85% of all kidney cancer [2]. Despite great achievement in diagnosis and therapy, because of the *Correspondence: [email protected] 1 Department of Urology, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China Full list of author information is available at the end of the article
characteristics of high metastasis risk and poor response to radiotherapy and chemotherapy, the most of patients with advanced kidney cancer are still difficult to be cured and prolong the survival time [3]. Therefore, it is necessary to clarify the underling mechanism and find several clinically effective diagnostic and prognostic biomarkers to prevent its occurrence and re-occurrence. Ser
Data Loading...
